The Official Newspaper of the University of Leeds since 1897

The Official Newspaper of the University of Leeds. Writing inspiring and meaningful stories since 1897

Cancer Vaccine Shows Potential

0

Vaccines have been used for decades to prevent and treat infectious diseases. Their successful application has inspired researchers to explore the possibility of developing vaccines against cancer.

50727457726_0c58090329_w

“This is an exciting advance in the field of cancer vaccines”.

Vaccines have been used for decades to prevent and treat infectious diseases. Their successful application has inspired researchers to explore the possibility of developing vaccines against cancer.

The goal of a cancer vaccine is to stimulate the body’s immune system to attack and eliminate cancer cells. However, developing effective cancer vaccines has proven to be challenging, due to the complexity of the disease. Cancers often vary greatly between individuals and even within the same tumour. Despite the challenges, there has recently been renewed interest in cancer vaccine research. This has been driven by breakthroughs in vaccine technology, such as the mRNA technology used in COVID-19 vaccines.

Melenomas are some of the deadliest forms of skin cancer. Image: Flickr

Recently, promising results have emerged from a phase 2 clinical trial which tested personalised mRNA vaccines for melanoma, the deadliest form of skin cancer. The vaccine targets unique mutations in a patient’s cancer while sparing healthy cells in the body. The trial recruited 157 patients previously treated for melanoma, who were also at high risk of experiencing a recurrence of their cancers. Whilst all patients received the immunotherapy drug Keytruda (the standard treatment for high-risk melanoma), 107 patients also received the personalised vaccine. Results showed only 22.4% of patients who received both treatments experienced a recurrence of their cancer during a two-year followed up period, compared to 40% of patients who received only the immunotherapy drug. This represents a difference of 44% between the two groups.

The new study findings have been called “an exciting advance in the field of cancer vaccines.” Image: Flickr

Dr Antoni Rabas, a professor of medicine at the University of California, described the significance of this personalised mRNA vaccine. He stated to NBC News: “It’s the first time a cancer vaccine has been shown to have this level of benefit, close to 50% decrease in the risk of relapse”. The potential of this personalised mRNA vaccine represents a novel approach to treatment, tailored to a patient’s specific cancer.

The researchers anticipate that the upcoming phase 3 trial, scheduled to launch this summer, will yield similar promising results. Margaret Callahan, from the Memorial Sloan Kettering Cancer Centre called this “an exciting advance in the field of cancer vaccines”.

Leave a Reply

Your email address will not be published. Required fields are marked *

Weather

High: 13°C

Low: 8°C

Rain: 78%

Sunset: 08:07 PM

As an independent media outlet, we hold the University and the Union to account where possible. We provide a range of content that is of interest to students and residents of Leeds.

×

Write for Us

We are always looking for talented writers to contribute to the Gryphon! If you have a passion for newspapers (or writting in general), we encourage you to submit your work. Please review the following guidelines before submitting your article:

Original Content: We only accept original articles that have not been previously published elsewhere.
Writing Style: Use a clear and concise writing style, and ensure your article is well-structured and easy to read.
Images: If you include images, please ensure you have the necessary rights to use them. Provide appropriate attribution.

We will review your submission and notify you. If your article is selected for publication. We reserve the right to edit articles for clarity and style.

×

Advertise With Us

Looking to connect with engaged readers? The Gryphon offers a unique platform to showcase your brand and reach a Student population.

Why Advertise with Us?

Targeted Reach: Connect with a specific demographic interested in Local news, arts & culture and student life.

High Engagement: Our readers are actively involved and value the content we provide.
Multiple Opportunities: We offer a range of advertising options to suit your needs and budget, including banner ads and sponsored content.

Interested in learning more?
Contact us at editor@thegryphon.co.uk to discuss advertising opportunities and rates. We look forward to partnering with you!

Contact Us

editor@thegryphon.co.uk


Issues with website?